By continuing browsing this website, you accept the use of cookies
to help us improve your user experience.

I agree
Loading... (0%)
About liver disease

GENFIT: A GLOBAL APPROACH TO THE DISEASE

Facilitate identification and referrals of NASH patients.
LEARN MORE
Phase 3 study of elafibranor in NASH with fibrosis is currently enrolling patients around the world.
LEARN MORE

COMPANY LIFE

GENFIT is a biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

Documentation Available
READ MORE
Online Voting Tutorial (Votaccess app. - French version)
DOWNLOAD

The NASH Education Program™

Health prevention, medical education, dissemination of relevant information related to NASH disease

ACCESS THE NASH EDUCATION PROGRAM™ WEBSITE
Press releases
  • GENFIT: Ordinary and Extraordinary Shareholders' Meeting of june 15, 2018 - Availability of Preparatory Documents
    05/09/2018
  • GENFIT: Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
    04/23/2018
  • GENFIT: Major Milestone for the RESOLVE-IT Phase 3 Trial on the Recruitment of the Interim Analysis Cohort
    04/11/2018
  • GENFIT: Official Launch of the NASH Pediatric Program, following PIP and PSP Agreement by EMA and FDA
    01/23/2018
  • GENFIT: Contributing Significantly to the European LITMUS Initiative on NASH Biomarkers
    11/27/2017
Events
5e289b27b9283fcc6323fcafd9a0f2e4555555555555555555555